Book contents
- Frontmatter
- Contents
- Contributors
- Preface
- PART I THE INFLAMMATORY RESPONSE – AN OVERVIEW
- PART II INDIVIDUAL CELL TYPES
- PART III CHEMICAL MEDIATORS
- PART IV IMMUNOPHARMACOLOGY
- PART V INFLAMMATORY DISEASES/HISTOLOGY
- PART VI ANIMAL MODELS OF INFLAMMATION
- 27 Models of Acute Inflammation – Air-Pouch, Peritonitis, and Ischemia-Reperfusion
- 28A Experimental Models of Glomerulonephritis
- 28B Glomerulonephritis and Ischemia Reperfusion Injury
- 29 Asthma
- 30 Animal Models of Rheumatoid Arthritis
- 31 Ocular Inflammation Models
- 32 Atherosclerosis in Experimental Animal Models
- 33 Oral Inflammation and Periodontitis
- 34 Pathogens and Inflammation
- Index
- References
30 - Animal Models of Rheumatoid Arthritis
from PART VI - ANIMAL MODELS OF INFLAMMATION
Published online by Cambridge University Press: 05 April 2014
With contributions by
Book contents
- Frontmatter
- Contents
- Contributors
- Preface
- PART I THE INFLAMMATORY RESPONSE – AN OVERVIEW
- PART II INDIVIDUAL CELL TYPES
- PART III CHEMICAL MEDIATORS
- PART IV IMMUNOPHARMACOLOGY
- PART V INFLAMMATORY DISEASES/HISTOLOGY
- PART VI ANIMAL MODELS OF INFLAMMATION
- 27 Models of Acute Inflammation – Air-Pouch, Peritonitis, and Ischemia-Reperfusion
- 28A Experimental Models of Glomerulonephritis
- 28B Glomerulonephritis and Ischemia Reperfusion Injury
- 29 Asthma
- 30 Animal Models of Rheumatoid Arthritis
- 31 Ocular Inflammation Models
- 32 Atherosclerosis in Experimental Animal Models
- 33 Oral Inflammation and Periodontitis
- 34 Pathogens and Inflammation
- Index
- References
Summary
RHEUMATOID ARTHRITIS
Rheumatoid arthritis (RA) is an extremely painful, debilitating, and destructive inflammatory disease of diarthrodial joints. It affects between 0.5% and 1% of the world's population, with women having a threefold prevalence. Using traditional therapy, the majority will develop moderate disability at 2 years, with 40% being unable to work at 5 years. The disease has a high cost in pain, disability, and deformity. Morbidity is high, with a reduced lifespan. The advent of new treatment paradigms has meant that disability has been reduced, orthopedic surgeries have a much reduced rheumatoid joint replacement case-load, and whilst still severe, the aim of therapy is to preserve normal lifestyle and work patterns.
This is achieved by the use of low-dose methotrexate, leflunomide, or sulphasalazine, followed by biologic therapies, mainly anti-tumor necrosis factor (anti-TNF-α), anti-B cell (anti-CD20), recombinant human IL-1 receptor antagonist (rhIL-1ra), or anti-interleukin-6 (anti-IL-6). There remains a severe problem that despite these regimes a significant proportion (up to 40% for anti-TNF-α) do not respond. In addition, these treatments are expensive in their own right, and heavy on clinical resources for administration and monitoring. There is thus a continuing requirement for the development of improved therapeutics through drug discovery and further development of current therapeutics and their targets. A detailed understanding of the pathogenic mechanisms of RA are also required to fulfill these aims. Animal models of rheumatic disease continue to play a significant role in this process.
- Type
- Chapter
- Information
- Fundamentals of Inflammation , pp. 385 - 412Publisher: Cambridge University PressPrint publication year: 2010
References
1. 2008. T cells in rheumatoid arthritis. Arthritis Res Ther 10(Suppl 1):S1.CrossRefGoogle ScholarPubMed
2. , and 2008. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev 223:175–185.CrossRefGoogle ScholarPubMed
3. 2008. Dynamic interactions between T cells and dendritic cells and their derived cytokines/chemokines in the rheumatoid synovium. Arthritis Res Ther 10(Suppl 1):S2.CrossRefGoogle Scholar
4. , and 2008. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118:3533–3546.CrossRefGoogle ScholarPubMed
5. , , and 1977. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 146(3):857–868.CrossRefGoogle ScholarPubMed
6. , and 2001. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 103(4):407–416.CrossRefGoogle ScholarPubMed
7. , , , and 2002. The molecular pathogenesis of collagen-induced arthritis in mice – a model for rheumatoid arthritis. Ageing Res Rev 1:135–147.CrossRefGoogle ScholarPubMed
8. , and 2006. Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther 8:223.CrossRefGoogle ScholarPubMed
9. , , , , , and 2007. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol. 179:1369–1380.CrossRefGoogle ScholarPubMed
10. 2004. Immunotherapy in collagen-induced arthritis: past, present, and future. Am J Med Sci 327(4):217–226.CrossRefGoogle ScholarPubMed
11. , , , , , and 1999. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 163(9):5049–5055.Google ScholarPubMed
12. , , , and 2008. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. Arthritis Rheum. 58(2 Suppl):S110–S122.Google ScholarPubMed
13. , , , , , and 1996. Organ-specific disease provoked by systemic autoimmunity. Cell 87(5):811–822.CrossRefGoogle ScholarPubMed
14. , and 2005. The role and clinical implications of G6PI in experimental models of rheumatoid arthritis. Arthritis Res Ther 7(1):20–28.CrossRefGoogle ScholarPubMed
15. 1992. Characterisation and pharmacological sensitivity of antigen arthritis induced by methylated bovine serum albumin in the rat. Inflamm Res 35(1–2):88–95.Google ScholarPubMed
16. , , 1989. The effects of different sensitisation protocols on arthritic responses in antigen-induced arthritis. Inflamm Res 27:338–340.Google Scholar
17. , , , , and 1982. Antigen handling in antigen-induced arthritis in mice an autoradiographic and immunofluorescence study using whole joint sections. Am J Pathol 108:9–16.Google ScholarPubMed
18. , , and 1987. Studies on the effects of pharmacological agents on antigen-induced arthritis in BALB/c mice. Drugs Exp Clin Res 13(5):273–277.Google ScholarPubMed
19. 2003. The assessment of inflammation, cartilage matrix and bone loss in experimental mono-articular arthritis in the rat. Methods Mol Biol 225:161–174.Google Scholar
20. , , , et al. 2002. Antiarthritic activity of an orally active c5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum 46:2476–2485.CrossRefGoogle ScholarPubMed
21. , , , et al. 2005. Expression of cytokine mRNA and protein in joints and lymphoid organs during the course of rat antigen-induced arthritis. Arthritis Res Ther 7:R445–R457.CrossRefGoogle ScholarPubMed
22. , and 2005. The modulation of intra-articular inflammation, cartilage matrix and bone loss in mono-articular arthritis induced by heat-killed Myobacterium tuberculosis. Inflammopharmacology 12(5–6):551–567.CrossRefGoogle Scholar
23. , , , et al. 2002. Inflammation, immune reactivity, and angiogenesis in a severe combined immunodeficiency model of rheumatoid arthritis. Am J Pathol 160:357–367.CrossRefGoogle Scholar
24. , , , et al. 2000. Tumour necrosis factor-alpha (TNF-a) enhances lymphocyte migration into rheumatoid synovial tissue transplanted into severe combined immunodeficient (SCID) mice. Clin Exp Immunol 122:133–142.CrossRefGoogle Scholar
25. , , , et al. 2009. Ectopic lymphoid structures support ongoing production of class switched autoantibodies in rheumatoid syn-ovium. PLoS Med 6(1):e1.CrossRefGoogle Scholar
26. , , and 2006. Rat models of arthritis: similarities, differences, advantages and disadvantages in the identification of novel therapeutics. In: In vivo Models of Inflammation. Progress in Inflammation Research. (ed.), 2nd Ed., Vol 1., pp. 1–34. Basel: Birkhauser.Google Scholar
27. , , , et al. 2005. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated strep-tococcal cell wall-induced arthritis. Arthritis Rheum 52:3239–3247.CrossRefGoogle ScholarPubMed
28. 1989. Streptococcal cell wall-induced polyarthritis in the rat. Mechanisms for chronicity and regulation of susceptibility. APMIS 97:861–878.Google Scholar
29. , , and 1991. Streptococcal cell wall-induced arthritis and adjuvant arthritis in F344 – Lewis and in Lewis – F344 bone marrow chimeras. Cell Immunol 136(2):278–290.CrossRefGoogle ScholarPubMed
30. , , , et al. 2001. Arthritis induced in rats with non-immunogenic adjuvants as models for rheumatoid arthritis. Immunol Rev 184:184–202.CrossRefGoogle Scholar
31. , , , et al. 2007. The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmu-nity in rats with pristane-induced arthritis. J Immunol 179:7568–7576.CrossRefGoogle ScholarPubMed
, , and 2008. Recent developments in the immunobiology of rheumatoid arthritis. Arthritis Res Ther 10(2):204. Epub March 14, 2008.CrossRefGoogle ScholarPubMed
, , , and 2009. Animal models of rheumatoid arthritis. Eur J Immunol. 39(8):2040–2044.CrossRefGoogle ScholarPubMed
1983. Models of arthritis and the search for anti-arthritic drugs. Pharmacol Ther 21:389–428.CrossRefGoogle ScholarPubMed
, , , and 2008. Utility of animal models for identification of potential therapeutics for Rheumatoid Arthritis. Ann Rheum Dis 67:1505–1515.CrossRefGoogle ScholarPubMed
, , and (eds.) 1995. Mechanisms and Models in Rheumatoid Arthritis. London: Academic Press.
, and 2006. Murine collagen-induced arthritis. In: In Vivo Models of Inflammation. Progress in Inflammation Research. (ed.), 2nd Ed., Vol 1, pp. 1–34. Basel: Birkhauser.Google Scholar
, , and 2005. Animal Models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 12:167–181.CrossRefGoogle ScholarPubMed
, , and 1986. Studies on type-II collagen induced arthritis in mice. Inflamm Res 18:413–420.Google ScholarPubMed
, , , , and 2004. Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. Clin Exp Immunol 137:65–73.CrossRefGoogle ScholarPubMed
, , , , and 2008. How do anti-rheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum 58:2936–2948.CrossRefGoogle ScholarPubMed
2009. Development of disease-modifying treatments for rheumatoid arthritis. Pharm J 282:191–192.Google Scholar
, and (eds.) Angiogenesis in Inflammation: Mechanisms and Clinical Correlates. Progress in Inflammation Research. Basel: Birkhauser.
, , and (Eds.) 2006. In Vivo Models of Inflammation, 2nd Ed., Vol 1. Progress in Inflammation Research. Basel: Birkhauser.CrossRef
, , and (Eds.) 2006. In Vivo Models of Inflammation, Vol 2. Progress in Inflammation Research. Basel: Birkhauser.CrossRef
(Ed.) 2009. New Therapeutic Targets in Rheumatoid Arthritis. Progress in Inflammation Research. Basel: Birkhauser.CrossRef
, and (Eds.) 2004. Cytokines and Joint Injury. Progress in Inflammation Research. Basel: Birkhauser.CrossRef
, , , , and 2007. Amplifying elements of arthritis and joint destruction. Ann Rheum Dis 666(s3):iii45–iii48.Google Scholar
2008. Immunotherapy in collagen-induced arthritis: past, present, and future. Am J Med Sci. 327:217–226.Google Scholar
- 2
- Cited by